FDA批准NovoCure的Optune Pax:全球首款用于局部晚期胰腺癌成人患者的创新疗法

美股速递
Feb 12

美国食品药品监督管理局(FDA)已正式批准NovoCure Limited(NASDAQ: NVCR)研发的Optune Pax设备上市。该设备是全球首款专门用于治疗局部晚期胰腺癌成人患者的创新医疗器械,标志着胰腺癌治疗领域取得重大突破。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10